Bonfanti P, Niero F, Ricci E, Iemoli E, Valsecchi L, Timillero L, Landonio S, Faggion I, Alessi F, Cinelli R, Parazzini F, Quirino T. "HAART tolerability: post-exposure prophylaxis in healthcare workers versus treatment in HIV infected patients." Antivir Ther 2000; 5 (S5): 51-52

Bonfanti P, Ricci E, Landonio S, Faggion I, Valsecchi L, Carradori S, Pusterla L, Fortuna P, Timillero L, Alessi F, Ghiselli G, Gabbuti A, Martinelli C, Parazzini F, Quirino T. "Adverse events in patients treated with protease inhibitors: a cohort study". Antivir Ther 2000; 5 (S5): 52

Bonfanti P, Ricci E, Faggion I, Valsecchi L, Carradori S, Pusterla L, Fortuna P, Timillero L, Alessi F, Ghiselli G, Gabbuti A, Martinelli C, Parazzini F, Landonio S, Quirino T. "Role of nucleoside reverse transcriptase inhibitors in causing adverse events in the HAART-treated patients". AIDS 2000; 14 (S4): 65-66

Bonfanti P, Quirino T, Faggion I, Valsecchi L, Carradori S, Pusterla L, Fortuna P, Timillero L, Miccolis S, Magnani C, Gabbuti A, Cinelli R, Martinelli C, Landonio S, Parazzini F, Vigevani GM "Reasons for protease inhibitor discontinuation in a selected cohort of HIV patients" Antivir Ther 2001; 6 (S4): 30

Quirino T, Bonfanti P, Faggion I, Ricci E, Valsecchi L, Carradori S, Pusterla L, Fortuna P, Timillero L, Miccolis S, Magnani C, Landonio S, Gabbuti A, Cinelli R, Parazzini F, Vigevani GM "Risk factors for hepatotoxixity in patients treated with highly active antiretroviral therapy: a cohort study" Antivir Ther 2001; 6 (S4): 13

Quirino T, Bonfanti P, Faggion I, Ricci E, Martinelli C, Valsecchi L, Carradori S, Pusterla L, Fortuna P, Timillero L, Miccolis S, Magnani C, Landonio S, gabbati A, Vigevani GM. "Glucose metabolism abnormalities associated with highly active antiretroviral therapy: a cohort study." Antivir Ther 2002; 7: L25

Quirino T, Bonfanti P, Chebat E, Faggion I, Martinelli C, Giuntini R, Valsecchi L, Carradori S, Landonio S, Gabbuti A, Gulisano C, Vigevani GM "Thyroid abnormalities in patients receiving highly active antiretroviral therapy" Antivir Ther 2002; 7: L62

Bonfanti P, Quirino T, Landonio S, Faggion I, Parazzini F, Vigevani GM. ". "The SCOLTA project: an on-line Italian post-marketing surveillance method for reporting adverse reactions to antiretrovirals drugs." Antivir Ther 2002; 7: L64.

Bonfanti P, Quirino T, Ricci E, Magnani C, Martinelli C, Cristina G, Migliorini D, Orofino G, Landonio S, Gulisano C, Carradori S, Madeddu G, Sfara C, Miccolis S, Vigevani GM. "Progetto Scolta: un metodo di farmacovigilanza sui farmaci antiretrovirali" Giorn It Mal Inf 2003; 9: (S1): 199

Quirino T, Bonfanti P, Gabris A, Boccassini L, Gulisano C, Landonio S, Vulpio L, Faggion I, Carrabba M, Vigevani GM. "Osteopenia e osteoporosi in pazienti con infezione da HIV" Giorn It Mal Inf 2003; 9: (S1): 200

Quirino T, Bongiovanni M, Ricci E, Bonfanti P, Chebat E, Martinelli C, Valsecchi L, Carradori S, Landonio S, Bini T, Gabbati A, Giuntini R, Gulisano C, Vigevani GM. "Subcinical hypothiroidism in HIV positive patients: is it iatrogenic or HIV related" Antivir Ther 2003; 8: L 91

Martinelli C, Giuntini R, Landonio S, Quirino T, Bonfanti P, Ruffino I, Massi D, Vigevani GM, Leoncini F. "Utility of patch testing in Hiv patients with cutaneous adverse reaction to highly active antiretroviral therapy". J Eur Acad Dermatol Venereol 2004; 18 (S2): 424-425

Bonfanti P, Facchetti R, Melzi S, Bombelli M, Cordier L, Franzetti M, Polo Friz H, Sfara C, Quirino T, Sega R. Metabolic Syndrome and HIV: comparison with the prevalence in the general population (SIMONE vs. PAMELA). Antiviral Therapy 2005; 10: L23

Bonfanti P, Ricci E, Landonio S, Franzetti M, Melzi S, Grosso C, Pusterla L, Carradori S, Martinelli C, Giustini R, Penco G, Miccolis S, Cordier L, Quirino T. Prevalenza della Sindrome Metabolica in una popolazione di HIV-positivi: lo studio SIM1. Giorn It Mal Inf 2005; 11: (S1): S147

Bonfanti P, Ricci E, Rusconi S, Martinelli C, Carradori S, Magnani C, Cristina G, De Socio G, Parruti G, Orofino G, Migliorini D, QuirinoT. Incidence of adverse reactions and reasons of treatment discontinuation in patients treated with Lopinavir/r in the SCOLTA Project cohort. Antiviral Therapy 2006; 11: L65